Related Experiment Videos
Cefotaxime treatment of meningitis in children
Insights
Cefotaxime effectively treated purulent meningitis in tropical regions, achieving a high cure rate. This antibiotic offers significant hope for children facing this severe infection, especially those with malnutrition or hemoglobinopathy.
Area of Science:
- Pediatrics
- Infectious Diseases
- Tropical Medicine
Background:
- Purulent meningitis poses a severe threat, particularly in tropical regions due to factors like malnutrition and delayed treatment.
- Prevalence of malnutrition, hemoglobinopathy, and enzymopathy exacerbates meningitis severity in tropical populations.
- Timely and effective treatment is critical for improving outcomes in pediatric meningitis.
Purpose of the Study:
- To evaluate the efficacy and safety of cefotaxime in treating purulent meningitis in children in a tropical setting.
- To assess the impact of cefotaxime on recovery rates in pediatric patients with purulent meningitis, considering underlying health conditions.
- To establish a benchmark for treatment success in a resource-limited environment.
Main Methods:
- A cohort of 28 pediatric patients (16 boys, 12 girls) aged 16 days to 7 years with purulent meningitis were treated with cefotaxime.
- Cefotaxime was administered intramuscularly at doses ranging from 90 to 200 mg/kg/day (mean 150 mg/kg/day), given 2 or 3 times daily.
- Patient data included age, sex, nutritional status, hemoglobinopathy, and treatment outcomes.
Main Results:
- An overall cure rate of 79% was achieved with cefotaxime treatment.
- Complete recovery was observed in 71% of the treated patients, representing the highest rate recorded in the department.
- Nearly half of the patients presented with malnutrition, low body weight, or hemoglobinopathy, highlighting the challenges in this population.
Conclusions:
- Cefotaxime demonstrates high efficacy in treating purulent meningitis in children within tropical areas.
- The observed cure and complete recovery rates underscore the effectiveness of cefotaxime, even in a population with significant comorbidities.
- These findings support the use of cefotaxime as a primary treatment option for purulent meningitis in resource-limited tropical settings.
Abstract:
Dangerous in all circumstances, purulent meningitis is even more life-threatening in tropical areas. This results from underlying malnutrition, haemoglobinopathy and enzymopathy, but also from delays in treatment. We have treated 28 patients, 16 boys and 12 girls, aged from 16 days to 7 years suffering from purulent meningitis, with cefotaxime. Almost half of the patients were suffering from malnutrition and low body weight, or from haemoglobinopathy. Cefotaxime, administered 2 or 3 times daily intramuscularly, was given at 90 to 200/mg/kg with a mean of 150/mg/kg/day. Overall, results showed a 79% cure rate including 71% complete recovery, the highest ever seen in the department.